Home
This site is intended for healthcare professionals
Advertisement

Mayo Clinic's grant to advance multiethnic Alzheimer’s research. Nilufer Ertekin-Taner, M.D., Ph.D.

30th Nov 2023
7:00 - 8:00pm (GMT)
30th Nov 2023
7:00 - 8:00pm (GMT)
Hosted on MedAll
This event has ended. Similar events
Free
ONLINE

Description

Dr. Nilüfer Ertekin-Taner, a renowned physician-scientist and professor at Mayo Clinic, is spearheading a transformative $41 million research program known as CLEAR-AD. This initiative focuses on advancing Alzheimer's research within multiethnic populations, including traditionally understudied groups like African Americans and Latino Americans. The program aims to identify precision medicine biomarkers and therapeutic targets for Alzheimer's by analyzing blood and brain tissue samples. This research is funded by a National Institutes of Health grant and seeks to understand the molecular underpinnings of the disease. Ultimately, it aspires to predict Alzheimer's development, the speed of progression, and discover precision medicine treatments. Collaborating with several institutions, Dr. Ertekin-Taner's work highlights the urgency of addressing Alzheimer's disease and emphasizes inclusivity in medical research.

Summary

Come learn from Dr. Nilüfer Ertekin-Taner, Mayo Clinic's leading expert on Alzheimer's disease research, as she presents her progressive program to advance multiethnic research in Alzheimer's at a special medical session. The program, funded by a generous NIH grant, focuses on identifying biomarkers and therapeutic targets in the blood and brain tissue of understudied multiethnic populations to create new strategies for predicting the progression and discovering effective treatments of the disease. Don't miss this opportunity to hear about this groundbreaking research and contribute to a collective effort to further medical progress.

Generated by MedBot

Learning objectives

  1. Learners should be able to articulate the purpose of the CLEAR-AD research program.
  2. Learners should be able to explain how the program seeks to identify precision medicine biomarkers and therapeutic targets for Alzheimer's.
  3. Learners should be able to identify the funding sources and the institutions collaborating for the CLEAR-AD program.
  4. Learners should be able to recognize the importance of inclusivity in research in traditionally understudied multiethnic populations.
  5. Learners should be able to describe the ultimate goal of the program, which is to predict Alzheimer's progression and discover precision medicine treatments.
Generated by MedBot

Speaking at this event

Advertisement
Advertisement
View all

Similar events and on demand videos

Advertisement
 
30th Nov 2023
7:00 - 8:00pm (GMT)
Hosted on MedAll
This event has ended. Similar events
Free
ONLINE